To the Editor:

We report on 6 systemic fibrinolysis uses for suspected PE among 53 cases with severe coronavirus 2 (SARS-CoV-2) pneumonia managed in our intensive care unit (ICU) since March 23 2020 ([Table 1](#tbl0005){ref-type="table"} ).Table 1Characteristics of patients treated with rescue systemic fibrinolysis.Table 1Patient123--13--245Age (years)674163635546SexMaleMaleMaleMaleMaleMaleBMI (kg/m^2^)26.225.827.227.220.724.3SAPS II262247472831Invasive MVNoYesYesYesYesYesNumber of PP sessions011114PaO~2~/FiO~2~ ratio (mmHg)808580919462PaCO~2~ (mmHg)365676465353Respiratory system compliance (ml/cmH~2~O)NA3330161710Driving pressure (cmH~2~O)NA1215252316NE dose (μg/kg/min)2.940.221.062.050.253.46VV-ECMONoNoNoNoNoYesAntithrombotic regimenCurative LMWHPreventive LMWHCurative LMWHCurative UFHCurative LMWHCurative UFHD-Dimer (ng/ml)2281NA4208420877949943PR (%)646777717080Platelet count (Giga/l)355194391403199176Fibrinogen (g/l)7.78.47.06.46.54.8Reason for fibrinolysisCACAShockShockShockShockImagingACPACP + CFV thrombosisACPACPACPACPComplications--------Femoral hemorrhage: 8 RBC transfusedJugular + femoral hemorrhage: 3 RBC transfusedImmediate effectNo ROSCNo ROSC60% NE decrease in 1 hPersistent shockPersistent shock80% NE decrease in 3 hVital statusDeathDeathDeath 3 days laterDeath 2 days laterDeath 3 days laterAlive at 7 days[^1][^2]

PE was suspected in 5 patients on combination of obstructive shock or unexpected cardiac arrest (CA) and acute cor pulmonale (ACP) on transthoracic echocardiography. Systemic fibrinolysis consisted of 100 mg Alteplase (Boehringer Ingelheim, France) intravenously. The conditions of 2 patients (\#3--1 and \#5) with obstructive shock improved, with a decreased norepinephrine dose shortly after fibrinolysis. However, another rescue therapy for the second hit did not succeed (\#3--2), leading to multi-organ failure despite veno-arterial extracorporeal membrane oxygenation (V-A ECMO) support. Fibrinolysis in patient \#4 did not resolve shock, requiring V-A ECMO. Circumstances of CA were typical: during prone to supine position mobilization (\#2) or after tracheal intubation (\#1). Chest compressions were performed during 1 h after therapy, without return of spontaneous circulation. Among survivors, thrombolytic therapy was complicated with major hemorrhage requiring transfusion.

Here, we discuss on the interest of fibrinolysis, because no specific report is available to date in the setting of COVID-19. Since high incidence of thromboembolic events (25--40%) was reported in SARS-CoV-2 patients,[@bib0005] the majority of our ICU patients was treated with therapeutic doses of anticoagulant agents. Whereas systemic fibrinolysis is the treatment of choice in PE-related shock or CA in the absence of contraindication,[@bib0010] how could this poor outcome be explained? First, PE may be oversuspected, because ACP does not systematically mean PE diagnosis. Indeed, ACP can be described in as many as 22% cases of acute respiratory distress syndrome (ARDS) due to lung vascular dysfunction driven by inflammation, thrombosis, fluid overload and two hits (pneumonia and mechanical ventilation).[@bib0015] Risk factors of ACP are pneumonia as cause of ARDS, severe hypoxemia, hypercapnia, elevated driving pressure, all these elements being encountered in the most severe COVID-19 patients. Second, poor prognosis could be the consequence of deleterious association of 2 severe conditions, namely, ARDS and PE-related shock or CA. At least, COVID-19 pneumonia is to date a dreadful disease, with around 50% mortality in ICU.[@bib0020]

In conclusion, despite favorable benefit/risk ratio in medical patients, we highlight that rescue systemic fibrinolysis in suspected PE is associated with poor outcome and that ACP should not always lead to PE diagnosis. To our sense, lower limbs ultrasound should systematically complete echocardiography to search for venous thrombosis, providing further clues for PE diagnosis in case of shock/CA.[@bib0025] Further studies are required to appreciate the place of systemic fibrinolysis during SARS-CoV-2 pandemic.
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[^1]: All clinical characteristics are reported before initiation of rescue therapy.

[^2]: *Abbreviations*: ACP: acute cor pulmonale, BMI: body mass index, CA: cardiac arrest, CFV: common femoral vein, h: hour, LMWH: low molecular weight heparin, MV: mechanical ventilation, NA: not applied, NE: norepinephrine, PC: platelet concentrate, PE: pulmonary embolism, PP: prone position, PR: prothrombin ratio, RBC: red blood cell, ROSC: return of spontaneous circulation, SAPS II: simplified acute physiology score II, UFH: unfractioned heparin, VV-ECMO: veno-venous extracorporeal membrane oxygenation.
